Home Nav
Nextech Invest Logo

news

News

02.07.2018

Kura Oncology

Kura Oncology announces closing of public offering and full exercise of option to purchase additional shares

29.06.2018

Neon Therapeutics

Neon Therapeutics announces closing of initial public offering

28.06.2018

Kura Oncology

Kura Oncology announces pricing of USD 67 million public offering of common stock

27.06.2018

Kura Oncology

Kura Oncology announces commencement of public offering of common stock

26.06.2018

Neon Therapeutics

Neon Therapeutics announces pricing of initial public offering

26.06.2018

Autolus

Autolus announces closing of initial public offering and full exercise of underwriters’ option to purchase additional American depositary shares

22.06.2018

Autolus

Autolus announces pricing of initial public offering

22.06.2018

ImaginAb

ImaginAb reconstitutes Japanese subsidiary

21.06.2018

Blueprint Medicines

Blueprint Medicines initiates VOYAGER Phase 3 clinical trial of avapritinib in patients with advanced gastrointestinal stromal tumors

20.06.2018

Kura Oncology

Kura Oncology appoints chief operating officer, expands clinical development team as company prepares for first registration-directed trial

15.06.2018

Blueprint Medicines

Blueprint Medicines announces updated data from ongoing Phase 1 EXPLORER clinical trial of avapritinib in patients with advanced systemic mastocytosis showing profound and durable clinical activity

13.06.2018

Tracon Pharmaceuticals

Tracon Pharmaceuticals announces presentation of preclinical data from studies of TRC105 in combination with a PD-1 antibody in murine models of colorectal cancer

06.06.2018

IDEAYA Biosciences

IDEAYA Biosciences to present at the 2018 Jefferies global healthcare conference

05.06.2018

IDEAYA Biosciences

IDEAYA Biosciences appoints Paul Stone, J.D., as senior vice president and general counsel, head of operations and Mark Lackner, Ph.D., as vice president, head of biomarkers and synthetic lethal biology

04.06.2018

Blueprint Medicines

Blueprint Medicines and CStone Pharmaceuticals announce exclusive collaboration and license agreement to develop and commercialize avapritinib, BLU-554 and BLU-667 in Greater China

02.06.2018

Jounce Therapeutics

Jounce Therapeutics presents preliminary efficacy data from ongoing Phase 1/2 ICONIC Trial of JTX-2011 in patients with advanced cancers

30.05.2018

Tracon Pharmaceuticals

Tracon Pharmaceuticals appoints biotech industry veteran Mark Wiggins as chief business officer

30.05.2018

Peloton Therapeutics

Peloton Therapeutics initiates Phase 2 trial of oral HIF-2α inhibitor PT2977 for treatment of von Hippel-Lindau disease-associated kidney cancer

22.05.2018

Kura Oncology

Kura Oncology announces screening collaboration with OncoDNA

17.05.2018

ImaginAb

ImaginAb reconstitutes scientific advisory board

Newsletter

Keep me updated about investment opportunities in the area of oncology and life sciences.

Register


Latest Newsletters

July 2018June 2018April 2018October 2017May 2017February 2017

Close

Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.

Preview

* Compulsory fields

Close

Newsletter Registration

Your eMail have been successfully registered.

Close

This website uses cookies to provide you with the best possible service. By using our website, you consent to the use of cookies in accordance with our privacy policy. Here you can find out more.